{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:28:13Z","timestamp":1793982493958,"version":"4.8.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Oral ivermectin and topical benzyl benzoate are two common treatment options for scabies, but there is ongoing discussion regarding their relative safety and efficacy. A thorough synthesis of the available evidence is required to inform treatment decisions because of the clinical debate caused by the contradictory findings from current randomized controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted on evidence retrieved from PubMed, Scopus, Web of Science, and CENTRAL for RCTs up to August 2025. The primary outcome was the cure rate. Secondary outcomes included pruritus improvement and the incidence of adverse events. Stata MP v. 18 was used to pool outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten RCTs involving 1,105 patients were included. Cure rates showed no significant difference between ivermectin and benzyl benzoate at 1\u202fweek (RR: 1.07, 95% CI [0.88, 1.30],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.51), 2\u20134\u202fweeks (RR: 0.99, 95% CI [0.88, 1.12],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.91), or after more than 4\u202fweeks (RR: 1.16, 95% CI [0.95, 1.43],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.15). The overall pooled result confirmed no difference (RR: 1.04, 95% CI [0.95, 1.14],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.37). For pruritus, no significant differences were observed at 1\u202fweek (RR: 1.07, 95% CI [0.80, 1.43],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.66), 2\u20134\u202fweeks (RR: 1.19, 95% CI [0.97, 1.46],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.09), or beyond 4\u202fweeks (RR: 1.10, 95% CI [0.89, 1.37],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.38); overall RR: 1.13, 95% CI [0.99, 1.29],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.07. Ivermectin showed significantly fewer adverse events (RR: 0.27, 95% CI [0.16, 0.46],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), particularly less burning\/stinging (RR: 0.07, 95% CI [0.02, 0.20],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Gastrointestinal (GI) events were not significantly different (RR: 1.47, 95% CI [0.67, 3.22],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.34).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oral ivermectin and topical benzyl benzoate exhibit comparable efficacy for the treatment of scabies. However, ivermectin\u2019s significantly better safety and tolerability, combined with the practical advantage of oral administration, establish it as a valuable and often preferable therapeutic choice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>CRD420251143937.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1703912","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:01:24Z","timestamp":1762430484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of oral ivermectin versus benzyl benzoate for the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Ahmed","family":"Abu-Zaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoor Ahmad","family":"AlBdah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latifa","family":"AlKandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Retaj S.","family":"Aljuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaikha T. H.","family":"Alhussaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawraa Yaqoub","family":"Alqallaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fai M.","family":"Alsaleeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashed Ahmed Soud","family":"Alhusaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danah S.","family":"Alrasheedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumanah Abdulrahman","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ashkanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Alharran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref1","year":""},{"key":"ref2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bjd.18943","article-title":"The 2020 international Alliance for the control of Scabies consensus criteria for the diagnosis of Scabies","volume":"183","author":"Engelman","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMcp052784","article-title":"Clinical practices. Scabies","volume":"354","author":"Chosidow","year":"2006","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/09546634.2016.1151855","article-title":"Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies","volume":"27","author":"Abdel-Raheem","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.pcl.2009.09.002","article-title":"Skin disorders, including pyoderma, Scabies, and tinea infections","volume":"56","author":"Andrews","year":"2009","journal-title":"Pediatr Clin N Am"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2471\/BLT.08.052308","article-title":"Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial","volume":"87","author":"Ly","year":"2009","journal-title":"Bull World Health Organ"},{"key":"ref7","first-page":"107","article-title":"European guideline for the management of scabies","volume":"11","author":"\u00c7etin","year":"2017","journal-title":"Cocuk Enfeksiyon Derg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1111\/jdv.17339","article-title":"Is scabies becoming less sensitive to permethrin therapy?","volume":"35","author":"Mazzatenta","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","first-page":"562","article-title":"Mass treatment with ivermectin: an underutilized public health strategy","volume":"82","author":"Speare","year":"2004","journal-title":"Bull World Health Organ"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0253-7613.48882","article-title":"Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies","volume":"41","author":"Bachewar","year":"2009","journal-title":"Indian J Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1046\/j.1440-1754.2002.00015.x","article-title":"Ivermectin is better than benzyl benzoate for childhood scabies in developing countries","volume":"38","author":"Brooks","year":"2002","journal-title":"J Paediatr Child Health"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.18231\/j.ijced.2021.010","article-title":"Study of efficacy and cost effectiveness of topical permethrin, benzyl benzoate and oral ivermectin in the treatment of scabies","volume":"7","author":"Mallya","year":"2021","journal-title":"IP Indian J Clin Exp Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/004947550103100105","article-title":"Successful treatment of scabies with oral ivermectin in Nigeria","volume":"31","author":"Nnoruka","year":"2001","journal-title":"Trop Dr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/jdv.18573","article-title":"Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: a randomized study","volume":"37","author":"Meyersburg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"Rating quality of evidence and strength of recommendations: what is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ Br Med J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.18203\/2320-6012.ijrms20195549","article-title":"Comparative study of oral ivermectin, topical permethrin and benzyl benzoate in the treatment of scabies","volume":"7","author":"Babu","year":"2019","journal-title":"Int J Res Med Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.18203\/2319-2003.ijbcp20201744","article-title":"Prospective, randomized, and comparative study of efficacy of ivermectin, benzyl benzoate 25%, permethrin 5% and gamma benzene hexachloride 1% in the treatment of uncomplicated scabies","volume":"9","author":"Chitra","year":"2020","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7860\/JCDR\/2014\/9092.4878","article-title":"Comparative study of efficacy of Oral ivermectin versus some topical Antiscabies drugs in the treatment of Scabies","volume":"8","author":"Manjhi","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/ddg.13706","article-title":"Increase of scabies in Germany and development of resistant mites? Evidence and consequences","volume":"17","author":"Sunderk\u00f6tter","year":"2019","journal-title":"JDDG"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ad.2022.05.036","article-title":"RF - resistance to permethrin in Scabies treatment: does it really exist?","volume":"114","author":"Velasco-Amador","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fmed.2021.628392","article-title":"Itch in Scabies\u2014what do we know?","volume":"8","author":"St\u00e4nder","year":"2021","journal-title":"Front Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13071-017-2234-1","article-title":"A review of Sarcoptes scabiei: past, present and future","volume":"10","author":"Arlian","year":"2017","journal-title":"Parasites Vect"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56025","article-title":"Ivermectin: a multifaceted drug with a potential beyond anti-parasitic therapy","author":"Kaur","year":"2024","journal-title":"Cureus"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/all.13118","article-title":"Topical ivermectin improves allergic skin inflammation","volume":"72","author":"Ventre","year":"2017","journal-title":"Allergy"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","article-title":"Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflamm Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5455\/ijavms.20101125120753","article-title":"Comparative therapeutic efficacy of permethrin, benzyl benzoate and sulfur in the treatment of scabies patients","volume":"3","author":"Mushtaq","year":"2009","journal-title":"Int J Agro Vet Med Sci"},{"key":"ref33","first-page":"637","article-title":"Pediculosis and scabies: treatment update","volume":"99","author":"Gunning","year":"2019","journal-title":"Am Fam Physician"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jiac.2023.12.012","article-title":"Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand","volume":"30","author":"Mikamo","year":"2024","journal-title":"J Infect Chemother"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"CD000320","DOI":"10.1002\/14651858.CD000320.pub2","article-title":"Interventions for treating scabies","volume":"2007","author":"Strong","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5603\/FD.2022.0017","article-title":"Scabies \u2014 review of the current diagnostic criteria and treatment recommendations","volume":"8","author":"Krawczyk","year":"2022","journal-title":"Forum Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/jdv.14351","article-title":"European guideline for the management of scabies","volume":"31","author":"Salavastru","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1703912\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:01:25Z","timestamp":1762430485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1703912\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":37,"alternative-id":["10.3389\/fmed.2025.1703912"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1703912","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1703912"}}